Stereotactic Body Radiotherapy And Focal Adhesion Kinase Inhibitor In Advanced Pancreas Adenocarcinoma

Study Overview

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Patients with advanced pancreas adenocarcinoma will be randomized on a 6:1 basis to receive standard of care chemotherapy followed by adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant FAK inhibitor defactinib (experimental arm) or standard of care chemotherapy followed by SBRT (control arm). Patients enrolled to the experimental arm will be assessed for clinical outcomes such as progression free survival (PFS), local control, distant control, and toxicity. The initial 6 patients randomized to the experimental arm will be considered the safety lead-in and will be assessed for dose-limiting toxicities (DLTs). Following completion of the safety lead-in, additional patients will be accrued in order to reach a total of 36 patients on the experimental arm (inclusive of the safety lead-in cohort) and 6 on the control arm.

N/A

Pancreas Cancer
Cancer of the Pancreas
Pancreas Adenocarcinoma

DEVICE: Adaptive stereotactic body radiation therapy
DRUG: Defactinib
PROCEDURE: Tumor biopsy
PROCEDURE: Research blood draw

202106061
R01CA248917-01 (U.S. NIH Grant/Contract)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2020-03-30	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2025-06-18
First Submitted that Met QC Criteria 2020-03-30	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2025-06-25
First Posted (ACTUAL) 2020-04-02	Results First Posted N/A	Last Verified 2025-06

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Randomized

Interventional Model:
Parallel

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Adaptive SBRT + Defactinib * Participants in this study will receive 5 fractions of magnetic resonance adaptive stereotactic body radiation therapy (SBRT) and seventeen 21-day cycles of defactinib (beginning on Day 2 of radiation). * Participants who are candidates for surgical res	DEVICE: Adaptive stereotactic body radiation therapy * Will be administered using MRIdian and Ethos * 50 Gy in 5 fractions DRUG: Defactinib -Oral drug 400 mg twice a day PROCEDURE: Tumor biopsy -Baseline and 12-14 weeks after end of SBRT (or at time of surgery) PROCEDURE: Research blood draw -Baseline, 6-8 weeks after the end of SBRT, and 12-14 weeks after the end of SBRT
ACTIVE_COMPARATOR: Adaptive SBRT -Participants in this study will receive 5 fractions of magnetic resonance adaptive stereotactic body radiation therapy (SBRT)	DEVICE: Adaptive stereotactic body radiation therapy * Will be administered using MRIdian and Ethos * 50 Gy in 5 fractions DRUG: Defactinib -Oral drug 400 mg twice a day PROCEDURE: Tumor biopsy -Baseline and 12-14 weeks after end of SBRT (or at time of surgery) PROCEDURE: Research blood draw -Baseline, 6-8 weeks after the end of SBRT, and 12-14 weeks after the end of SBRT

Participant Group/Arm

Intervention/Treatment

EXPERIMENTAL: Adaptive SBRT + Defactinib

* Participants in this study will receive 5 fractions of magnetic resonance adaptive stereotactic body radiation therapy (SBRT) and seventeen 21-day cycles of defactinib (beginning on Day 2 of radiation). * Participants who are candidates for surgical res

DEVICE: Adaptive stereotactic body radiation therapy

* Will be administered using MRIdian and Ethos * 50 Gy in 5 fractions

DRUG: Defactinib

-Oral drug 400 mg twice a day

PROCEDURE: Tumor biopsy

-Baseline and 12-14 weeks after end of SBRT (or at time of surgery)

PROCEDURE: Research blood draw

-Baseline, 6-8 weeks after the end of SBRT, and 12-14 weeks after the end of SBRT

ACTIVE_COMPARATOR: Adaptive SBRT

-Participants in this study will receive 5 fractions of magnetic resonance adaptive stereotactic body radiation therapy (SBRT)

DEVICE: Adaptive stereotactic body radiation therapy

* Will be administered using MRIdian and Ethos * 50 Gy in 5 fractions

DRUG: Defactinib

-Oral drug 400 mg twice a day

PROCEDURE: Tumor biopsy

-Baseline and 12-14 weeks after end of SBRT (or at time of surgery)

PROCEDURE: Research blood draw

-Baseline, 6-8 weeks after the end of SBRT, and 12-14 weeks after the end of SBRT

Primary Outcome Measures	Measure Description	Time Frame
Progression-free survival (PFS) (Experimental Arm only)	* PFS is defined as the duration of time from start of standard of care chemotherapy treatment to time of progression or death, whichever occurs first. The alive patients without progression will be censored at the last follow-up. * Progressive disease: At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).	After completion of treatment (estimated to be 12 months)

Secondary Outcome Measures	Measure Description	Time Frame
Number of participants with acute adverse events (Experimental Arm only)	-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for all toxicity reporting.	From start of adaptive SBRT through 90 days
Number of participants with late adverse events (Experimental Arm only)	-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for all toxicity reporting.	From 91 days through completion of follow-up (estimated to be 24 months)
Overall survival (Experimental Arm only)	-Overall survival as defined as the time from the date of treatment until death; censored at last follow-up if death is not observed	Through completion of follow-up (estimated to be 24 months)
Distant metastasis progression-free survival (DM-PFS) (Experimental Arm only)	-Defined as the days from the date of the treatment to distant metastasis progression or death	Through completion of follow-up (estimated to be 24 months)
Objective response rate (Experimental Arm only)	-Objective response rate as determined by RECIST 1.1 criteria, with one change. Patients who undergo resection will be considered to have a CR if there is a pathologic complete response (pCR) on the surgical specimen. After resection, patients will no longer be evaluated for ORR.	12-14 weeks post-adaptive SBRT
Local control (Experimental Arm only)	-Local control as defined by no progression of the primary tumor by RECIST 1.1 criteria	Through completion of follow-up (estimated to be 24 months)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Histologically or cytologically confirmed locally advanced pancreas adenocarcinoma that is considered borderline resectable or unresectable per institutional standardized criteria of unresectability or medical inoperability (NCCN guidelines 2.2021 PANC-C 1 of 2).
Patients with locoregional adenopathy are eligible as long as all suspicious lymph nodes are deemed to be adjacent to the primary tumor as per radiation oncologist assessment.
At least 3 months of systemic chemotherapy for this disease without progression of local or systemic disease. Newly diagnosed patients may be screened for enrollment in this study and can be enrolled once they have completed 3 months of systemic chemotherapy (and still meet all eligibility criteria) prior to the start of study treatment.
At least 18 years of age.
ECOG performance status ≤ 1
Life expectancy > 3 months
Normal bone marrow and organ function within 21 days of randomization as defined below:

Absolute neutrophil count ≥ 1,500/mcL
Platelets ≥ 100,000/mcL
Hemoglobin ≥ 9.0 g/dL
Total bilirubin ≤ 1.5 x IULN; no prior history of Gilbert's syndrome
AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN or ≤ 5.0 x IULN if due to liver involvement by tumor
Creatinine clearance ≤ 1.5 x IULN or glomerular filtration rate of ≥ 60 mL/min
INR ≤ 1.5 x IULN unless patient is receiving anticoagulant therapy as long as INR or PTT is within therapeutic range of intended use of anticoagulants
aPTT ≤ 1.5 x IULN unless patient is receiving anticoagulant therapy as long as INR or PTT is within therapeutic range of intended use of anticoagulants
Albumin ≥ 2.5 mg/dL
Corrected QT interval (QTc) < 480 ms (as calculated by the Fridericia correction formula).
The effects of defactinib on the developing human fetus are unknown. For this reason and because radiation therapy is known to be teratogenic, women of childbearing potential and men must agree to use highly effective contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and 120 days after completion of the study
Ability to understand and willingness to sign an IRB approved written informed consent document

A history of other malignancy with the exception of malignancies for which all treatment was completed at least 2 years before registration and the patient has no evidence of disease.
Clinical evident ascites or pleural effusion that requires therapeutic paracentesis or thoracentesis.
Prior treatment with a drug of the FAK inhibitor class or with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
Prior anti-human antibody response (AHA or ADA).
Currently receiving any other investigational agents or has receive any other investigational agents within 4 weeks or 5 half-lives or planned first dose of study agents.
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to defactinib or other agents used in the study.
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy not routinely associated with chemotherapeutic regimen.
Requires continued use of warfarin for anticoagulation and cannot stop warfarin or be safely switched to another anticoagulant or direct oral anticoagulant
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, hypertension, immunosuppression, autoimmune conditions, or underlying pulmonary disease.
Has an active autoimmune disease requiring systemic treatment within the past 2 years (i.e. with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
Received a live vaccine within 30 days prior to the first study treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. FluMist) are live attenuated vaccines and are not allowed.
Known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (defined as HCV RNA [qualitative] is detected).
Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
Has a known history of active TB (bacillus tuberculosis).
Major surgery within 28 days prior to the first study treatment.
Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
Patients with HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.
Known SARS-Cov2 infection ≤28 days prior to first dose of study therapy.
Exposure to P-glycoprotein (P-gp) inhibitors or inducers within 14 days prior to the first dose and during the course of therapy.
Subjects with the inability to swallow oral medications or impaired gastrointestinal absorption due to gastrectomy or active inflammatory bowel disease.
Subjects with a history of hypersensitivity to any of the inactive ingredients (hydroxypropylmethylcellulose, mannitol, magnesium stearate) of the investigational product.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

National Cancer Institute (NCI)
Verastem, Inc.

Investigators

PRINCIPAL_INVESTIGATOR: Hyun Kim, M.D., Washington University School of Medicine

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Fard D, Giraudo E, Tamagnone L. Mind the (guidance) signals! Translational relevance of semaphorins, plexins, and neuropilins in pancreatic cancer. Trends Mol Med. 2023 Oct;29(10):817-829. doi: 10.1016/j.molmed.2023.07.009. Epub 2023 Aug 17.

Learn

Resources

PatientS

Caregivers

Clinical Trial Record